BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.

Andere talen Beijing Tiantan Biological Products Co., Ltd.

Aandelen

600161

CNE000000WF9

Farmaceutische producten

Slotkoers Shanghai S.E. Andere beurzen 12-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
16,34 ^CNY	-1,98%		-4,44%	-20,29%

05/12	Beijing Tiantan Biological Products Rondt Fase Drie Proeven Af voor Protrombinecomplex	MT
20/11	Dochteronderneming van Tiantan Biological Products trekt aanvraag voor geneesmiddelregistratie stollingsfactor VIIa in	MT

Andere talen

Beijing Tiantan Biological Products Completes Phase Three Trials for Prothrombin Complex	05/12
Tiantan Biological Products' Subsidiary Withdraws Drug Registration Application for Coagulation Factor VIIa for Injection	20/11
Tiantan Biological Products' Q3 Profit Drops 43%, Revenue Rises 10%; Shares Down 2%	27/10
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	24/10
Tiantan Biological Products' Q3 net profit down 42.8% Y/Y	24/10
Tiantan Biological Products' Unit Completes Relocation of Human Coagulation Factor VIII's Production Site	10/10
Beijing Tiantan Biological Products Gets Local Good Manufacturing Practice Certificate for Anti-Clotting Injection	23/09
DIARY-China corporate earnings week ahead	12/09
Beijing Tiantan Biological Products' Attributable Profit Slides 13% in H1	22/08
Beijing Tiantan Biological Products H1 net profit down 12.9% Y/Y	21/08
Beijing Tiantan Biological Products' Trial on Hemophilia Drug Shows Positive Results	12/08
Tiantan Biological Products H1 Profit Down 13%, Revenue Up 9.5%	07/08
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	06/08
Tiantan Biological Products' prelim H1 net profit down 12.9% Y/Y	06/08
Tiantan Biological Products' Subsidiary Completes Phase III Trials on Hemophilia Drug; Shares Down 3%	06/08
Tiantan Biological Products Waives Pacific Shuanglin Bio-pharmacy Stake Buy	05/08
Beijing Tiantan Biological Products Gets Supplementary Drug Approval for Hemophilia A Injection	24/07
Tiantan Biological Products Starts Phase Three Trial for IV Immunoglobulin	18/07
Beijing Tiantan Biological Products Subsidiary Gets Good Manufacturing Practice Certification for Immunoglobulin Injection	25/06
Tiantan Biological Products Says Q1 Net Profit Down 22.9% Y/Y	25/04
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/04
Tiantan Biological Products 2024 Profit Up 40%, Revenue Climbs 16%	31/03
Beijing Tiantan Biological Products Co., Ltd. announces Annual dividend, payable on June 20, 2025	31/03
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	28/03
Tiantan Biological Products' 2024 Net Profit Up 39.6% Y/Y	28/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Beijing Tiantan Biological Products Co., Ltd.

Aandelen

600161

CNE000000WF9

Farmaceutische producten

Andere talen

Filters